In a nutshell This study aimed to investigate treatment-free remission after dasatinib treatment in patients with chronic-phase chronic myeloid leukemia. This study concluded that it is possible to stop dasatinib treatment in these patients once they have achieved a deep molecular response. Some...
Read More
In a nutshell This study aimed to compare the side effects associated of ibrutinib treatment for elderly patients with chronic lymphoid leukemia. This study concluded that ibrutinib treatment in these patients was not associated with significantly higher risks of anemia (low red blood cells), thrombocytopenia...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of obinutuzumab in combination with fludarabine and cyclophosphamide in fit patients with chronic lymphocytic leukemia. This study concluded that this combination as frontline treatment is a promising option for these...
Read MoreIn a nutshell This study aimed to investigate the long-term safety of ibrutinib as a single-agent treatment for patients with chronic lymphocytic leukemia. This study concluded that side effects were mainly grade 1 or 2 and were manageable during prolonged ibrutinib treatment in these patients. Some background...
Read More
In a nutshell This study aimed to investigate the ending of imatinib treatment in patients with chronic-phase chronic myeloid leukemia who had at least 2 years of deep molecular response from imatinib first line treatment. This study concluded that the duration of treatment and residual...
Read MoreIn a nutshell This study aimed to investigate the occurrence of second cancers in patients with chronic myeloid leukemia (CML). This study concluded that the occurrence of overall second cancers in these patients is slightly higher than that of the general population. Some background Tyrosine kinase inhibitors (TKIs) are commonly used for the...
Read More
In a nutshell This study looked at the effect of imatinib (Gleevec) on kidney function in patients with chronic myeloid leukemia (CML). Researchers found that a reversible decline in kidney function was linked with long-term imatinib use in these patients. Some background Imatinib is a strong drug used to treat CML. The kidney produces a hormone that...
Read More
In a nutshell This study looked at the effect of stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). Researchers found that stopping TKI therapy was safe in these patients under certain conditions. Some background Chronic myeloid leukemia is a cancer of the immune system. It is linked with...
Read More
In a nutshell This study looked at the risk of infections associated with ibrutinib (Imbruvica) used in the treatment of leukemia and lymphoma. Researchers found that patients receiving ibrutinib are at risk of serious infections. Some background Ibrutinib is a drug which targets certain proteins on cancer cells to stop them from working. It is often...
Read MoreIn a nutshell This study aimed to compare the outcomes of patients with chronic lymphocytic leukemia who received chemoimmunotherapy or ibrutinib. This study suggested that ibrutinib may have more favorable outcomes for these patients when compared to chemoimmunotherapy. Some background Chemoimmunotherapy (CIT) is a treatment option that can be used...
Read MoreIn a nutshell This study looked at the risk and outcomes of fluid build-up around the lungs in patients with leukemia receiving dasatinib (Sprycel) treatment. The study found that age was a risk factor for developing lung fluid in these patients but overall survival was not affected. Some background Leukemia is a cancer of the bone marrow that leads...
Read More
In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...
Read More
